Literature DB >> 18729327

Modification of serine 360 by a reactive intermediate of 17-alpha-ethynylestradiol results in mechanism-based inactivation of cytochrome P450s 2B1 and 2B6.

Ute M Kent1, Chitra Sridar, Greg Spahlinger, Paul F Hollenberg.   

Abstract

17-alpha-Ethynylestradiol (17EE) is a mechanism-based inactivator of P450 2B1 and P450 2B6 in the reconstituted monooxygenase system. The loss in enzymatic activity was due to the binding of a reactive intermediate of 17EE to the apoprotein. P450 2B1 and P450 2B6 were inactivated by 17EE and digested with trypsin. The peptides obtained following digestion with trypsin of 17EE-inactivated P450 2B1 and P450 2B6 were separated by liquid chromatography and analyzed by ESI-MS. Adducted peptides exhibiting an increase in mass consistent with the addition of the mass of the reactive intermediate of 17EE were identified for each enzyme. Analysis of these modified peptides by ESI-MS/MS and precursor ion scanning facilitated the identification of the Ser360 in both enzymes as a site that had been adducted by a reactive intermediate of 17EE. A P450 2B1 mutant where Ser360 was replaced by alanine was constructed, expressed, and purified. Activity and inactivation studies indicated that mutation of the Ser360 residue to alanine did not prevent inactivation of the mutant enzyme by 17EE. These observations suggest that Ser360 is not critical for the catalytic function of these P450s. Spectral binding studies of the 17EE-inactivated P450 2B1 and P450 2B6 indicated that modification of the enzymes by the reactive intermediate of 17EE resulted in an enzyme that was no longer capable of binding substrates. These results suggest that the inactivation by 17EE may be due to modification of an amino acid residue in the substrate access channel near the point of entry into the active site.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18729327      PMCID: PMC2772146          DOI: 10.1021/tx800138v

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  21 in total

Review 1.  Metabolism of estrogens--natural and synthetic.

Authors:  H M Bolt
Journal:  Pharmacol Ther       Date:  1979       Impact factor: 12.310

2.  Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities.

Authors:  I H Hanna; J F Teiber; K L Kokones; P F Hollenberg
Journal:  Arch Biochem Biophys       Date:  1998-02-15       Impact factor: 4.013

3.  Mechanism of inactivation of rat liver microsomal cytochrome P-450c by 2-bromo-4'-nitroacetophenone.

Authors:  A Parkinson; P E Thomas; D E Ryan; L D Gorsky; J E Shively; J M Sayer; D M Jerina; W Levin
Journal:  J Biol Chem       Date:  1986-09-05       Impact factor: 5.157

4.  Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl)imidazole at 1.9-A resolution: insight into the range of P450 conformations and the coordination of redox partner binding.

Authors:  Emily E Scott; Mark A White; You Ai He; Eric F Johnson; C David Stout; James R Halpert
Journal:  J Biol Chem       Date:  2004-04-20       Impact factor: 5.157

5.  Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver.

Authors:  D J Waxman; A Ko; C Walsh
Journal:  J Biol Chem       Date:  1983-10-10       Impact factor: 5.157

6.  Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6.

Authors:  Ute M Kent; Hsia-Lien Lin; Danielle E Mills; Kelly A Regal; Paul F Hollenberg
Journal:  Chem Res Toxicol       Date:  2006-02       Impact factor: 3.739

7.  Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450.

Authors:  F P Guengerich
Journal:  Mol Pharmacol       Date:  1988-05       Impact factor: 4.436

8.  Regio- and stereoselective metabolism of two C19 steroids by five highly purified and reconstituted rat hepatic cytochrome P-450 isozymes.

Authors:  A W Wood; D E Ryan; P E Thomas; W Levin
Journal:  J Biol Chem       Date:  1983-07-25       Impact factor: 5.157

9.  On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol.

Authors:  J R Halpert; N E Miller; L D Gorsky
Journal:  J Biol Chem       Date:  1985-07-15       Impact factor: 5.157

10.  Mechanistic studies of 9-ethynylphenanthrene-inactivated cytochrome P450 2B1.

Authors:  E S Roberts; D P Ballou; N E Hopkins; W L Alworth; P F Hollenberg
Journal:  Arch Biochem Biophys       Date:  1995-11-10       Impact factor: 4.013

View more
  5 in total

1.  Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tert-butylphenylacetylene.

Authors:  Hsia-lien Lin; Haoming Zhang; Matthew J Pratt-Hyatt; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2011-09-19       Impact factor: 3.922

Review 2.  Acetylenes: cytochrome P450 oxidation and mechanism-based enzyme inactivation.

Authors:  Paul R Ortiz de Montellano
Journal:  Drug Metab Rev       Date:  2019-07-07       Impact factor: 4.518

3.  Covalent modification of Thr302 in cytochrome P450 2B1 by the mechanism-based inactivator 4-tert-butylphenylacetylene.

Authors:  Hsia-lien Lin; Haoming Zhang; Monica Jushchyshyn; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2010-03-03       Impact factor: 4.030

Review 4.  Targeting of the highly conserved threonine 302 residue of cytochromes P450 2B family during mechanism-based inactivation by aryl acetylenes.

Authors:  Haoming Zhang; Hsia-lien Lin; Cesar Kenaan; Paul F Hollenberg
Journal:  Arch Biochem Biophys       Date:  2010-09-15       Impact factor: 4.013

5.  The Moderately (D)efficient Enzyme: Catalysis-Related Damage In Vivo and Its Repair.

Authors:  Ulschan Bathe; Bryan J Leong; Donald R McCarty; Christopher S Henry; Paul E Abraham; Mark A Wilson; Andrew D Hanson
Journal:  Biochemistry       Date:  2021-11-03       Impact factor: 3.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.